Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure
Hydration of Scars
Drug: Application of Aruba Aloë formula F-BC-096 or control
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
|Official Title:||A Prospective, Randomized, Double Blinded Controlled Clinical Trial of the Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure|
- Scar assessment after 1 month
- Scar assessment 3, 6 and 12 months after wound closure
Patients with two equal donor sites will be selected for inclusion. After wound healing one donor site will be treated with Aruba Aloë Formula F-BC-096 while a control product will be applied to the second site.
If pressure garments are applied they must be equal for both donor sites. During follow-ups objective methods will be used to evaluate elasticity and colour of the scar.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00389753
|University Hospital Ghent|
|Ghent, Belgium, 9000|
|Principal Investigator:||Stan Monstrey, MD, PhD||University Hospital, Ghent|